1
|
Hossain F, Sorrentino C, Ucar Bilyeu AD, Matossian M, Crabtree J, Pannuti A, Burow M, Golde T, Osborne B, Miele L. Abstract P6-07-06: Targeting cancer stem-like cells metabolism via non-canonical notch signaling pathways in triple negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-07-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancer (TNBC) is a heterogeneous group of clinically aggressive diseases. TNBC patients have high risk of recurrence and metastasis, and current treatment options remain limited. Cancer stem-like cells (CSCs) have been linked to cancer initiation, progression and chemotherapy resistance. Therefore CSC-targeted therapies are keenly sought. There is strong evidence for the involvement of Notch signaling in TNBC. Notch1 is highly expressed in Basal-like 1 (BL1) and especially Mesenchymal-Stem-Like (MSL) TNBCs. Expression of Notch1 and its ligand Jagged1 correlate with poor prognosis. Moreover, strong evidence supports key roles of different Notch paralogs in breast CSCs. Here, we demonstrate that Notch activation by Jagged1-expressing stromal cells enhances transcription of the anti-apoptotic gene cIAP-2 (BIRC3), a known NF-κB target. This event is dependent on recruitment to the cIAP-2 promoter of NF-κB subunits, IKKα and Notch1. Short term exposure of MDA-MB-231 cells (MSL, PTEN wild-type), but not MDA-MB-468 cells (BL1, PTEN-null) to recombinant Jagged1 leads to AKT phosphorylation. This is suppressed by AKT inhibitors, IKK inhibitors, and dual mTORC1/2 inhibitors but not an mTORC1-selective inhibitor. These observations support a model where canonical and non-canonical mechanisms downstream of Notch1 trigger AKT phosphorylation and NF-κB activation in PTEN wild type TNBC cells. Rapid AKT phosphorylation downstream of Notch1 requires mTORC2, PI3K and IKKα, and contributes to NF-κB activation. This suggests a bidirectional crosstalk between the IKKα and AKT arms of this Jagged1-activated pathway. Importantly, we find co-localization of Notch1 with Mitochondria in MDA-MB-231 cells by confocal microscopy and Western blot of isolated mitochondrial fractions. We demonstrate that recombinant Jagged1 increases metabolism of TNBC cells. Knockdown of Notch1 or IKKα by siRNA decreases mitochondrial respiration and glycolysis. CSCs derived from MDA-MB-231 cells have increased Notch1, p-AKT, and oxidative metabolism compared to non-stem cells. AKT inhibition or IKK inhibition decreases both mitochondrial respiration and glycolysis of TNBC derived CSCs. Pharmacological inhibition of Notch cleavage by gamma secretase inhibitor (PF-03084014) in combination with AKT inhibitor (MK-2206) or IKK inhibitor (Bay11-7082) blocks CD90hi or CD44+CD24low sorted secondary mammospheres formation. Notably, we find similar results in TNBC patient derived xenograft (PDX) models. These data suggest that combination treatments affecting the intersection of Notch, NF-kB and AKT pathways have potential therapeutic importance in targeting CSCs in TNBC cases with high Notch1 expression.
Citation Format: Hossain F, Sorrentino C, Ucar Bilyeu AD, Matossian M, Crabtree J, Pannuti A, Burow M, Golde T, Osborne B, Miele L. Targeting cancer stem-like cells metabolism via non-canonical notch signaling pathways in triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-07-06.
Collapse
Affiliation(s)
- F Hossain
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - C Sorrentino
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - AD Ucar Bilyeu
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - M Matossian
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - J Crabtree
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - A Pannuti
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - M Burow
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - T Golde
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - B Osborne
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - L Miele
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| |
Collapse
|
2
|
Matossian M, Burks H, Bowles A, Sabol R, Hoang V, Elliott S, Bunnell B, Zuercher W, Drewry D, Wells C, Alfortish A, Lee S, Hartono A, Jones S, Moroz K, Zea A, Burow M, Collins-Burow B. Abstract P5-05-05: Patient-derived triple negative breast cancer xenografts as a translational model to screen for novel kinase pathways. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-05-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Overall, triple negative breast cancers (TNBCs) constitute 12% of all breast cancers, and is approximately twice more prevalent in African-American populations. Louisiana has a high proportion of African-American residents (32.5% in 2015), and thus hosts a higher population of TNBC patients. TNBCs have an aggressive phenotype that is elusive to the targeted therapeutics used to treat other breast cancer subtypes. Certain kinase families have been extensively studied as regulators of epithelial-mesenchymal transition (EMT), a process involved in the initiation of cancer metastasis. Discovery of novel kinase targets within the subset of uncharacterized kinases could provide important insight into future targeted therapies. However, current models utilized in target discovery research are limited by the inability to accurately recapitulate the complex stromal architecture and heterogenous genetic and molecular composition of breast cancer. Furthermore, immortalized cell lines are limited to a 2D environment and over time acquire mutations that may not reflect the primary tumor. Recently, our laboratory has successfully established two TNBC patient-derived xenograft (PDX) models derived from African-American patients, and generated cell lines (TU-BCx-2K1, TU-BCx-2O0) and mammospheres. One of these models, 2O0, presents tumor architecture, cellular composition, genomic (qRT-PCR) and protein (western blot) expressions that are concordant with a claudin-low subtype, which has higher rates of metastasis and recurrence. Furthermore, we show that both TNBC models metastasize to the lungs, and exhibit molecular characteristics consistent with mesenchymal phenotypes. We utilized these translational PDX models to screen a library of small molecule inhibitors that represent a variety of kinase pathways to identify novel therapeutic targets and/or pathways that are specific to TNBC subtypes. We found in a preliminary cell morphology screen using three TNBC cell lines (MDA-MB-231, BT549, MDA-MB-157), two small molecule inhibitors that increased epithelial marker (CDH1) gene expression, suppressed mesenchymal (VIM, c-FOS, SNAI1, ZEB1) expression and/or suppressed cellular motility in transwell migration assays. We observed after ex vivo treatments with our PDX tumors the two compounds increase the epithelial marker CDH1 expression, and suppress mesenchymal markers (VIM, MMP2, c-FOS, SNAI1, ZEB1) expressions. We confirm these findings in the TU-BCx-2K1 cell line. Kinase array data revealed candidate kinases responsible for the observed EMT changes in the two compounds of interest (NEK5, NEK9, NEK1 potentially affect cell motility; SRC-family kinases, TAOK2, STK10 potentially affect EMT gene changes); we plan to utilize the PDX cell lines to characterize these kinases in EMT. We aim to ultimately discover novel therapeutic targets specific to different TNBC molecular subtypes.
Citation Format: Matossian M, Burks H, Bowles A, Sabol R, Hoang V, Elliott S, Bunnell B, Zuercher W, Drewry D, Wells C, Alfortish A, Lee S, Hartono A, Jones S, Moroz K, Zea A, Burow M, Collins-Burow B. Patient-derived triple negative breast cancer xenografts as a translational model to screen for novel kinase pathways [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-05-05.
Collapse
Affiliation(s)
- M Matossian
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - H Burks
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - A Bowles
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - R Sabol
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - V Hoang
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - S Elliott
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - B Bunnell
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - W Zuercher
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - D Drewry
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - C Wells
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - A Alfortish
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - S Lee
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - A Hartono
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - S Jones
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - K Moroz
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - A Zea
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - M Burow
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| | - B Collins-Burow
- Tulane University School of Medicine, New Orleans, LA; Eshelman School of Pharmacy, University of Chapel Hill, Chapel Hill, NC; Louisiana Cancer Research Center, New Orleans, LA
| |
Collapse
|
3
|
Matossian M, Vangelderen C, Papagerakis P, Zheng L, Wolf GT, Papagerakis S. In silico modeling of the molecular interactions of antacid medication with the endothelium: novel therapeutic implications in head and neck carcinomas. Int J Immunopathol Pharmacol 2015; 27:573-83. [PMID: 25572737 DOI: 10.1177/039463201402700413] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Pathological acid reflux is a common event in patients afflicted with head and neck squamous cell carcinomas (HNSCCs), known to play a role in HNSCC etiology and contribute to complications after surgery or during radiation and chemotherapy. Antacid medications are commonly prescribed in HNSCC patients as part of their cancer treatment, and consist of two classes: histamine 2 receptor antagonist class (H2RA, with cimetidine as its prototypical drug) and proton pump inhibitors class (PPI, with omeprazole as its prototypical drug). Clinical evidence revealed a significant survival benefit of antacid usage in a large cohort of HNSCC patients treated in our Otolaryngology Department, with a median follow-up of over 5 years. Therefore, we postulate that one mechanism by which antacid intake enhances patient survival could involve modulation of tumor cell adhesion to endothelium, critical in the initiation of the metastatic dissemination. This study investigates the potential physical interactions between cimetidine and omeprazole with the endothelial E-selection (E-sel) and its ligand sialyl Lewis X (sLe(x)) using a molecular visualization energy-based program (AutoDock). Docking results were further analyzed with the PyMOL program, which allowed for measurements of the distances between the drugs and the closest interacting atoms or residues on E-sel and sLe(x) molecules. Our model predicts that omeprazole displays a stronger interaction with E-sel than cimetidine, as extrapolated from the calculated overall binding energies. However, the shorter distances existing between interacting atoms in the proposed E-sel/cimetidine complex are suggestive of more stable interactions. Neither antacid/E-sel complex overcame the stronger Autodock-calculated sLe(x)/E-sel interaction, suggesting competitive inhibition was not involved. This study provides the first in silico evidence of omeprazole and cimetidine ability to bind to adhesion molecules involved in tumor dissemination, underlining their therapeutic potential in the HNSCC clinical management.
Collapse
Affiliation(s)
- M Matossian
- Departments of Otolaryngology/Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA
| | - C Vangelderen
- Department of Chemistry, Kalamazoo College, Kalamazoo, MI, USA
| | - P Papagerakis
- Departments of Orthodontics/Pediatric Dentistry, University of Michigan, Ann Arbor, MI, USA
| | - L Zheng
- Departments of Otolaryngology/Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA
| | - G T Wolf
- Departments of Otolaryngology/Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA
| | - S Papagerakis
- Departments of Otolaryngology/Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
4
|
Athanassiou-Papaefthymiou M, Shkeir O, Kim D, Divi V, Matossian M, Owen JH, Czerwinski MJ, Papagerakis P, McHugh J, Bradford CR, Carey TE, Wolf GT, Prince ME, Papagerakis S. Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance. Int J Immunopathol Pharmacol 2014; 27:337-49. [PMID: 25280025 DOI: 10.1177/039463201402700304] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Cancer stem cells possess the qualities of self-renewal, tumorigenesis and the ability to recapitulate a heterogeneous tumor. Our group was the first to isolate head and neck squamous cell carcinoma (HNSCC) stem cells using the cell surface marker CD44. CD44 is a trans-membrane glycoprotein with a multitude of key-functions that regulate cancer cell proliferation and metastasis. The variety of CD44 functions is due to tissue-specific patterns of glycosylation of the extracellular portion, and to the multiple protein isoforms (CD44 variants, CD44v) generated by alternative splicing. This study investigates the expression pattern of CD44 variants in HNSCC. Ten cell lines from the most common HNSCC locations and representative of various clinical outcomes were assayed by quantitative realtime PCR, flow cytometry and immunofluorescence comparatively with normal oral keratinocytes. The CD44 v4 and v6 were exclusively abundant in HNSCC while the isoform v1,2 was expressed in normal oral keratinocytes. Of interest, the highest level of CD44v6 expression was detected in advanced metastatic HNSCC, suggesting a link between CD44v6 expression and HNSCC metastasis, while the highest CD44v4 was detected in a stage IV HNSCC refractory to chemotherapy which developed recurrence. Oral-derived HNSCC expressed the highest CD44v4 and v6, and levels corresponded with staging, showing also an increasing tendency with recurrence and metastasis. CD44v were detected predominantly in smaller cells (a characteristic that has been associated with stem cell properties) or cells with mesenchymal morphology (a characteristic that has been associated with the migratory and invasive potential of epithelial tumor cells), suggesting that CD44v differential expression in HNSCC may be representative of the morphological changes inherent during tumor progression towards a more aggressive potential, and thus contributing to the individual tumor biology. The mechanism of CD44 variant involvement in HNSCC progression and metastasis is under investigation.
Collapse
Affiliation(s)
| | - O Shkeir
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| | - D Kim
- Department of Pediatric Dentistry and Orthodontics, University of Michigan, Ann Arbor, MI, USA
| | - V Divi
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| | - M Matossian
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| | - J H Owen
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| | - M J Czerwinski
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| | - P Papagerakis
- Department of Pediatric Dentistry and Orthodontics, University of Michigan, Ann Arbor, MI, USA
| | - J McHugh
- Department of Pathology, University of Michigan, Ann Arbor, MI, USA
| | - C R Bradford
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| | - T E Carey
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| | - G T Wolf
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| | - M E Prince
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| | - S Papagerakis
- Department of Otolaryngology, Head & Neck Surgery, University of Michigan, Ann Arbor, MI , USA
| |
Collapse
|